Trial intelligence / Profile preview

SUBSTITUTE: Basal Bolus Therapy (Insulin Glargine + Insulin Glulisine) in T1DM

NCT01204593Phase 4Completed

Sponsor
Sanofi
Start
Nov 2010
Primary completion
Jan 2013
Modality
Peptides, Recombinant Proteins and Enzymes
Countries
9
01

Overview

A Phase 4 trial of insulin glargine, insulin glulisine in type 1 diabetes mellitus (T1D), sponsored by Sanofi. Started Nov 2010; status: completed.

02

Drugs

insulin glargineinsulin glulisine
03

Conditions

type 1 diabetes mellitus (T1D)

Beyond the preview

Go deeper on NCT01204593.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01204593.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call